741 Pivotal phase 3 study in overactive bladder (OAB) patients with urinary incontinence confirms onabotulinumtoxinA 100U significantly improves all OAB symptoms and patients' quality of life

2013 ◽  
Vol 12 (1) ◽  
pp. e741-e742 ◽  
Author(s):  
C. Chapple ◽  
K-D. Sievert ◽  
S. MacDiarmid ◽  
V. Khullar ◽  
P. Radziszewski ◽  
...  
2019 ◽  
Vol 65 (4) ◽  
Author(s):  
Agnieszka Licow ◽  
Sylwester Ciećwież ◽  
Magdalena Ptak ◽  
Dariusz Kotlęga ◽  
Andrzej Starczewski ◽  
...  

Overactive bladder affects 12–17% of the population, and mainly women, and its incidence increases with age. Diagnosis of this condition is based mainly on the patients’ complaints. These symptoms significantly affect the quality of life of millions of patients, involving considerable social, psychological, professional, physical and sexual problems. The wide incidence of this condition makes it necessary to find new medical substances in order to effectively eliminate the symptoms. Neurotoxins are a group of medical drugs that hold great promise for the future. Botulinum toxin is currently being used to treat  symptoms related to overactive bladder. It can constitute an appropriate therapeutic option, in  particular with regard to patients for whom the use of standard anti-cholinergic drugs is unsatisfactory or leads to severe side effects. Numerous research studies confirm that botulinum toxin can be  efficiently used in the treatment of overactive bladder. The properties of this neurotoxin allow selective  deactivation of overactive muscles. The use of botulinum toxin can be a method of treatment that significantly improves patient quality of life.Keywords: botulinum toxin; overactive bladder; urinary incontinence; quality of life.


2005 ◽  
Vol 173 (4S) ◽  
pp. 2-2
Author(s):  
Karin S. Coyne ◽  
Mary Kay Margolis ◽  
Tamara Bavendam ◽  
Teresa Zyczynski ◽  
Rebecca Rogers

Sign in / Sign up

Export Citation Format

Share Document